Guenther Sabina P W, Schramm René, Teuteberg Jeffrey J, Shudo Yasuhiro, Rogge Anna L, Schaeper Katharina E, Fox Henrik, Hoepner Lisa, Ruaengsri Chawannuch, Costard-Jaeckle Angelika, Hiesinger William, Woo Y Joseph, Morshuis Michiel, Khush Kiran K, Gummert Jan F, Wayda Brian J
Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr-University Bochum, Bad Oeynhausen, Germany.
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Clin Transplant. 2025 Jun;39(6):e70214. doi: 10.1111/ctr.70214.
Consensus regarding what defines acceptable heart transplant (HT) donors or recipients is lacking. This survey analyzed how risk factors guide donor and recipient selection, and how practices vary across systems.
An online survey was conducted among adult HT centers in the US and Eurotransplant (ET) region. We aimed to represent at least 50% of the total adult HT volumes in both regions. Centers were stratified by their HT volumes. To compensate for non-responders, a safety margin was included, and centers accounting for at least 75% of the total HT volumes were contacted. Centers were queried on relative thresholds and absolute cutoffs for continuous risk factors. For other factors, their influence on donor heart acceptance or the likelihood of listing recipients was assessed.
Fifty-three centers from five countries participated: 39 US (accounting for 51.0% of the US HT volume), and 14 ET centers (65.0%) from four countries. ET centers more liberally considered advanced age donor hearts (threshold 64.5 [60.0-70.0] vs. 50.0 [50.0-55.0] years, p < 0.001), and hearts with abnormal echocardiography or coronary findings. Diabetes, smoking, and hypertension were rated by a quarter to more than half of US and ET centers as moderately or heavily influencing donor heart acceptance. ET centers more liberally listed candidates with chronic kidney disease (GFR 30.0 [21.5-32.5] vs. 35.0 [30.0-40.0] mL/min/1.73m, p < 0.001). US centers, conversely, allowed for higher candidate ages (71.5 [70.0-74.0] vs. 68.0 [65.0-70.0] years, p < 0.001), and more likely (76.9%) listed candidates on ECMO support (42.9% of ET centers to less likely list, p = 0.022).
Selection practices differed distinctly between the US and ET. Further, practices appear to be driven by caution and are more conservative than current guidelines. Strengthening the evidence base to objectify and optimize donor and candidate selection could help alleviate the unmet need for donor hearts.
目前对于可接受的心脏移植(HT)供体或受体的定义尚未达成共识。本调查分析了风险因素如何指导供体和受体的选择,以及各系统之间的做法差异。
在美国和欧洲移植(ET)地区的成人HT中心开展了一项在线调查。我们的目标是覆盖两个地区至少50%的成人HT总量。中心按其HT量进行分层。为了补偿未回复者,纳入了一个安全边际,并联系了占HT总量至少75%的中心。询问各中心关于连续风险因素的相对阈值和绝对临界值。对于其他因素,评估它们对供体心脏接受度或受体列入名单可能性的影响。
来自五个国家的53个中心参与了调查:39个美国中心(占美国HT量的51.0%),以及来自四个国家的14个ET中心(65.0%)。ET中心更宽松地考虑高龄供体心脏(阈值为64.5[60.0 - 70.0]岁,而美国为50.0[50.0 - 55.0]岁,p < 0.001),以及超声心动图或冠状动脉检查结果异常的心脏。四分之一到一半以上的美国和ET中心将糖尿病、吸烟和高血压评为对供体心脏接受度有中度或重大影响。ET中心更宽松地将慢性肾病患者列入名单(肾小球滤过率为30.0[21.5 - 32.5],而美国为35.0[30.0 - 40.0]mL/min/1.73m²,p < 0.001)。相反,美国中心允许更高的候选年龄(71.5[70.0 - 74.0]岁,而ET为68.0[65.0 - 70.0]岁,p < 0.001),并且更有可能(76.9%)将接受体外膜肺氧合(ECMO)支持的候选者列入名单(ET中心为42.9%,列入可能性较低,p = 0.022)。
美国和ET的选择做法存在明显差异。此外,这些做法似乎受到谨慎态度的驱动,并且比当前指南更为保守。加强证据基础以客观化和优化供体及候选者选择,可能有助于缓解对供体心脏未满足的需求。